ONYX PHARMACEUTICALS INC Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated statements of cash flows

In millions of USD, except per-share amounts

	FY2012 12 months to Dec 31, 2012	FY2011 12 months to Dec 31, 2011	FY2010 12 months to Dec 31, 2010
Cash flows from operating activities:
Net income (loss)
Adjustments to reconcile net income (loss) to net cash used in operating activities:
Deferred income taxes
Depreciation
Stock-based compensation
Amortization of convertible senior notes discount and debt issuance costs
Amortization of finite-lived intangible assets
Changes in fair value of liability for contingent consideration
Property and equipment write-off
Impairment of equity investment
Accretion of lease exit costs liability
Realized gains on sales of current marketable securities
Non-cash tax benefit
Changes in operating assets and liabilities:
Restricted cash
Accounts receivable
Receivable from collaboration partners
Inventory
Prepaid expenses and other current assets
Other assets
Accounts payable
Accrued liabilities
Accrued clinical trials and related expenses
Accrued compensation
Deferred revenue
Escrow liability
Lease termination exit costs liability
Other current liabilities
Other liabilities
Acquisition of Proteolix, Inc. net of cash acquired
Net cash (used in) provided by operating activities
Cash flows from investing activities:
Purchases of marketable securities
Sales of marketable securities
Maturities of marketable securities
Transfers from restricted cash
Payment for liability for contingent consideration, current
Capital expenditures
Repayment of notes payable
Repurchases of restricted stock awards
Net cash (used in) provided by investing activities
Cash flows from financing activities:
Repurchases of restricted stock awards
Payment to collaboration partner
Net proceeds from issuances of common stock
Proceeds from issuance of convertible senior notes
Convertible senior notes debt issuance costs
Excess tax benefit from stock-based awards
Net increase (decrease) in cash and cash equivalents
Net cash provided by financing activities
Net increase (decrease) in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental cash flow data
Cash paid during the period for income taxes
Cash paid during the period for interest
Equity issued in lieu of cash payment of contingent consideration liability

Comments